vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $80.1M, roughly 2.0× AMERISAFE INC). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 10.2%, a 61.0% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 10.3%).
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
AMSF vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $158.6M |
| Net Profit | $8.1M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | — | 70.2% |
| Net Margin | 10.2% | 71.2% |
| Revenue YoY | 10.3% | 3661.1% |
| Net Profit YoY | -9.0% | 528.0% |
| EPS (diluted) | $0.43 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | — | ||
| Q3 25 | $82.0M | — | ||
| Q2 25 | $81.1M | — | ||
| Q1 25 | $72.6M | $158.6M | ||
| Q4 24 | $74.0M | $22.6M | ||
| Q3 24 | $78.7M | — | ||
| Q2 24 | $75.8M | — |
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | — | ||
| Q3 25 | $13.8M | — | ||
| Q2 25 | $14.0M | — | ||
| Q1 25 | $8.9M | $112.9M | ||
| Q4 24 | $13.2M | $-10.5M | ||
| Q3 24 | $14.3M | — | ||
| Q2 24 | $11.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | — | ||
| Q3 25 | 21.3% | — | ||
| Q2 25 | 21.5% | — | ||
| Q1 25 | 15.5% | 70.2% | ||
| Q4 24 | 22.7% | -60.4% | ||
| Q3 24 | 22.6% | — | ||
| Q2 24 | 18.1% | — |
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | 16.9% | — | ||
| Q2 25 | 17.2% | — | ||
| Q1 25 | 12.3% | 71.2% | ||
| Q4 24 | 17.8% | -46.4% | ||
| Q3 24 | 18.2% | — | ||
| Q2 24 | 14.5% | — |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | — | ||
| Q3 25 | $0.72 | — | ||
| Q2 25 | $0.73 | — | ||
| Q1 25 | $0.47 | $1.90 | ||
| Q4 24 | $0.69 | $-0.15 | ||
| Q3 24 | $0.75 | — | ||
| Q2 24 | $0.57 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.6M | $350.1M |
| Total Assets | — | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | — | ||
| Q3 25 | $54.7M | — | ||
| Q2 25 | $48.5M | — | ||
| Q1 25 | $44.8M | $274.8M | ||
| Q4 24 | $44.1M | $128.0M | ||
| Q3 24 | $63.7M | — | ||
| Q2 24 | $30.6M | — |
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | — | ||
| Q3 25 | $274.8M | — | ||
| Q2 25 | $265.6M | — | ||
| Q1 25 | $260.8M | $350.1M | ||
| Q4 24 | $257.3M | $229.0M | ||
| Q3 24 | $314.4M | — | ||
| Q2 24 | $301.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | $406.9M | ||
| Q4 24 | $1.2B | $271.6M | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | — | ||
| Q3 25 | $10.7M | — | ||
| Q2 25 | $-8.4M | — | ||
| Q1 25 | $-1.8M | $131.8M | ||
| Q4 24 | $24.2M | $-23.2M | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $-2.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | — | ||
| Q3 25 | $9.8M | — | ||
| Q2 25 | $-9.5M | — | ||
| Q1 25 | $-1.8M | $131.7M | ||
| Q4 24 | $23.4M | $-23.2M | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $-2.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | -11.7% | — | ||
| Q1 25 | -2.5% | 83.0% | ||
| Q4 24 | 31.5% | -102.7% | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | -3.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 1.1% | 0.2% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | -0.61× | — | ||
| Q1 25 | -0.20× | 1.17× | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | -0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
